Andrew Saik Sells 11,139 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik sold 11,139 shares of Arvinas stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the transaction, the chief financial officer directly owned 193,128 shares of the company’s stock, valued at approximately $1,919,692.32. This represents a 5.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Saik also recently made the following trade(s):

• On Friday, February 13th, Andrew Saik sold 5,134 shares of Arvinas stock. The stock was sold at an average price of $11.89, for a total value of $61,043.26.

Arvinas Stock Performance

Shares of ARVN traded up $0.30 during trading hours on Wednesday, hitting $9.87. The company had a trading volume of 787,117 shares, compared to its average volume of 855,453. The firm has a fifty day moving average price of $11.21 and a 200-day moving average price of $11.68. The stock has a market capitalization of $636.81 million, a price-to-earnings ratio of -7.71 and a beta of 1.79. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $14.51.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.05. The firm had revenue of $15.60 million during the quarter, compared to analyst estimates of $16.61 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.Arvinas’s quarterly revenue was down 91.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.14 EPS. Research analysts anticipate that Arvinas, Inc. will post -3.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ARVN has been the subject of several recent analyst reports. Citigroup lifted their price target on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. BTIG Research lifted their price target on Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays lifted their price target on Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday. Zacks Research lowered Arvinas from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Arvinas has an average rating of “Hold” and an average price target of $15.14.

Institutional Investors Weigh In On Arvinas

Large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in shares of Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares during the period. Canada Pension Plan Investment Board grew its stake in shares of Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares during the period. State of Wyoming bought a new stake in shares of Arvinas during the 3rd quarter valued at about $68,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Arvinas during the 3rd quarter valued at about $92,000. Finally, Jain Global LLC bought a new stake in shares of Arvinas during the 3rd quarter valued at about $95,000. 95.19% of the stock is currently owned by institutional investors.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, suggesting meaningful upside from current levels. BTIG raises Arvinas price target
• Positive Sentiment: Arvinas and Pfizer struck a licensing deal with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), bringing in $85 million upfront and transition payments plus up to $320 million in additional milestones and royalties. Arvinas and Pfizer deal with Rigel
• Positive Sentiment: The company said VEPPANU became the first FDA-approved PROTAC, which validates Arvinas’ drug-degradation platform and supports its pipeline story. Arvinas Q1 2026 results and corporate update
• Neutral Sentiment: First-quarter results were mixed: Arvinas reported a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply from a year ago. Arvinas Q1 earnings report
• Neutral Sentiment: Investors are also watching pre-earnings commentary and transcript coverage, but these items appear more informational than market-moving on their own. Arvinas earnings call transcript
• Negative Sentiment: Despite the product and licensing progress, Arvinas remains unprofitable with weak revenue trends, which may temper enthusiasm for the stock’s longer-term fundamentals. Arvinas earnings expectations

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.